Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ActiveMatrix for Spinal Surgical Site Infection Reduction
NCT05297513Phase 4Not yet recruiting
- Sponsor
- Baylor College of Medicine
- Start
- Jul 2022
- Primary completion
- Jul 2025
01
Overview
Phase 4, randomised, single-blind trial of ActiveMatrix in surgical site infection (SSI) (2 arms), sponsored by Baylor College of Medicine. Primary endpoint: Surgical Site Infection at 90 days. Planned start Jul 2022; status: not yet recruiting.
02
Drugs
ActiveMatrix
03
Conditions
surgical site infection (SSI)
Beyond the preview
Go deeper on NCT05297513.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05297513.